Cargando…

Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing

KRAS is the most frequently mutated oncogene in human cancer, and its activating mutations represent long-sought therapeutic targets. Programmable nucleases, particularly the CRISPR-Cas9 system, provide an attractive tool for genetically targeting KRAS mutations in cancer cells. Here, we show that c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sayed, Shady, Sidorova, Olga A., Hennig, Alexander, Augsburg, Martina, Cortés Vesga, Catherine P., Abohawya, Moustafa, Schmitt, Lukas T., Sürün, Duran, Stange, Daniel E., Mircetic, Jovan, Buchholz, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Genome and Epigenome
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437569/ https://www.ncbi.nlm.nih.gov/pubmed/35802645 http://dx.doi.org/10.1158/0008-5472.CAN-21-2519

Ejemplares similares

DNA methylation–independent long-term epigenetic silencing with dCRISPR/Cas9 fusion proteins
por: Ding, Li, et al.
Publicado: (2022)

CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
por: Jiang, Long, et al.
Publicado: (2022)

FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits
por: Tsai, Jessica W., et al.
Publicado: (2022)

Combinatorial CRISPR/Cas9 Screening Reveals Epistatic Networks of Interacting Tumor Suppressor Genes and Therapeutic Targets in Human Breast Cancer
por: Zhao, Xiaoyu, et al.
Publicado: (2021)

Efficient Generation and Correction of Mutations in Human iPS Cells Utilizing mRNAs of CRISPR Base Editors and Prime Editors
por: Sürün, Duran, et al.
Publicado: (2020)

CRISPR prime editing for unconstrained correction of oncogenic KRAS variants
por: Jang, Gayoung, et al.
Publicado: (2023)

PAX9 Determines Epigenetic State Transition and Cell Fate in Cancer
por: Zhao, Zibo, et al.
Publicado: (2021)

Regulatory Network of PD1 Signaling Is Associated with Prognosis in Glioblastoma Multiforme
por: Lopes-Ramos, Camila M., et al.
Publicado: (2021)

The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer
por: Patel, Monal, et al.
Publicado: (2021)

Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell Survival
por: Gillani, Riaz, et al.
Publicado: (2021)

Clonal Hematopoiesis Mutations in Patients with Lung Cancer Are Associated with Lung Cancer Risk Factors
por: Hong, Wei, et al.
Publicado: (2022)

Association of Genetic Ancestry and Molecular Signatures with Cancer Survival Disparities: A Pan-Cancer Analysis
por: Lee, Kara Keun, et al.
Publicado: (2022)

Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer
por: Patel, Achal, et al.
Publicado: (2022)

Leveraging Allele-Specific Expression for Therapeutic Response Gene Discovery in Glioblastoma
por: Sen, Arko, et al.
Publicado: (2022)

Antisense RNAs Influence Promoter Usage of Their Counterpart Sense Genes in Cancer
por: Bellido Molias, Fernando, et al.
Publicado: (2021)

Comprehensive Analysis of Alternative Splicing in Gastric Cancer Identifies Epithelial–Mesenchymal Transition Subtypes Associated with Survival
por: Jun, Yukyung, et al.
Publicado: (2022)

LncRNA Uc003xsl.1-Mediated Activation of the NFκB/IL8 Axis Promotes Progression of Triple-Negative Breast Cancer
por: Xu, Ying, et al.
Publicado: (2022)

Genomic Profiling of Bronchoalveolar Lavage Fluid in Lung Cancer
por: Nair, Viswam S., et al.
Publicado: (2022)

The Prostate Cancer Androgen Receptor Cistrome in African American Men Associates with Upregulation of Lipid Metabolism and Immune Response
por: Berchuck, Jacob E., et al.
Publicado: (2022)

Genetic Ancestry Inference from Cancer-Derived Molecular Data across Genomic and Transcriptomic Platforms
por: Belleau, Pascal, et al.
Publicado: (2023)

Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer
por: Hua, Xu, et al.
Publicado: (2023)

Genetic Determinants of Somatic Selection of Mutational Processes in 3,566 Human Cancers
por: Guo, Jintao, et al.
Publicado: (2021)

Pan-Cancer Analysis of Canonical and Modified miRNAs Enhances the Resolution of the Functional miRNAome in Cancer
por: Distefano, Rosario, et al.
Publicado: (2022)

The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
por: Sjöström, Martin, et al.
Publicado: (2022)

Single-Cell Dissection of the Multiomic Landscape of High-Grade Serous Ovarian Cancer
por: Wang, Yicheng, et al.
Publicado: (2022)

Immunogenetic Determinants of Susceptibility to Head and Neck Cancer in the Million Veteran Program Cohort
por: Liu, Yanhong, et al.
Publicado: (2023)

Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma
por: Yu, Zhenyuan, et al.
Publicado: (2023)

KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer
por: Qiu, Hong, et al.
Publicado: (2023)

DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations
por: Gallon, John, et al.
Publicado: (2023)

Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma
por: Yao, Lijun, et al.
Publicado: (2023)

G-Quadruplex Structures Are Key Modulators of Somatic Structural Variants in Cancers
por: Zhang, Rongxin, et al.
Publicado: (2023)

SWI/SNF Blockade Disrupts PU.1-Directed Enhancer Programs in Normal Hematopoietic Cells and Acute Myeloid Leukemia
por: Chambers, Courtney, et al.
Publicado: (2023)

Quantification of evolved DNA-editing enzymes at scale with DEQSeq
por: Schmitt, Lukas Theo, et al.
Publicado: (2023)

High Efficiency Gene Correction in Hematopoietic Cells by Donor-Template-Free CRISPR/Cas9 Genome Editing
por: Sürün, Duran, et al.
Publicado: (2017)

METB-01. EXTRACHROMOSOMAL DNA IS ASSOCIATED WITH ONCOGENE AMPLIFICATION AND POOR SURVIVAL ACROSS MULTIPLE PEDIATRIC CANCER TYPES
por: Sridhar, Sunita, et al.
Publicado: (2023)

Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?
por: Mirgayazova, Regina, et al.
Publicado: (2020)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells
por: Lee, Wookjae, et al.
Publicado: (2018)

Induction of pancreatic neoplasia in the KRAS/TP53 Oncopig
por: Mondal, Pinaki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_okljlkh7juioa8cg9f3ans9d6h